Biogen rose by 18billion on FDA approval of its drug for Alzheimers. Just an example of what is possible. Clinuvel is targeting stroke, skin cancer and anti aging /dna repair. A sixth indication is mooted, probably brain related, possibly Alzheimers itself. Melanocortin receptor activation restores cell homeostasis, repairs BBB and restores blood supply via NOS. If any of these indications gets up then we may have an 18billion day also. That would be $360 a share rise. If that is not worth a punt I don't know what is. Downside from here is? not much. Already approved, generating cash.
Clinuvel compared to Imugene, page-11
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.58 |
Change
-0.930(6.00%) |
Mkt cap ! $730.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $4.173M | 285.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.58 | 1486 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |